Ligustrazine attenuates acute lung injury after burn trauma.
Acute lung injury is a common complication in patients with extensive burns in which the burned area exceeds 30% of the total body surface area (TBSA). This study was undertaken to evaluate the effect of Ligustrazine on burn-induced lung injury as well as the release of interleukin-8 (IL-8) in rats to characterize the role of Ligustrazine and IL-8 in lung injury after burn trauma. Sprague-dawley rats were divided into three groups: (1) sham group, rats who underwent sham burn; (2) control group, rats given third-degree burns over 30% TBSA and lactated Ringer solution for resuscitation; and (3) Ligustrazine group, rats given burn injury and lactated Ringer's solution with Ligustrazine inside for resuscitation. Pulmonary injury was assessed at 24 h by pulmonary capillary permeability determined with fluorescein isothiocyanate-labeled albumin and lung histologic analysis, and lung myeloperoxidase (MPO) activity as well as lung wet/dry weight ratio. The IL-8 levels were measured in serum by enzyme-linked immunosorbent assay. These studies showed that burn trauma results in increased pulmonary leakage permeability and lung wet/dry ratio, elevated serum IL-8 levels and MPO activity, and worsened histologic condition. Ligustrazine inhibited these changes, prevented burn-mediated lung injury, and the production of IL-8. This will likely provide further evidence for ligustrazine as a therapeutic strategy in burn-induced lung injury.
Zheng
Hong
H
Department of Pathophysiology, Anhui Medical University, Hefei, Anhui 230032, PR China.
Chen
Xu-Lin
XL
Han
Zhi-Xun
ZX
Zhang
Zhi
Z
Wang
Si-Ying
SY
Xu
Qing-Lian
QL
D000208:Acute Disease; D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use*; D002056:Burns / Q000097:blood / Q000150:complications* / Q000188:drug therapy; D002199:Capillary Permeability; D016209:Interleukin-8 / Q000097:blood; D008168:Lung / Q000201:enzymology / Q000276:immunology / Q000503:physiopathology; D008297:Male; D023421:Models, Animal; D009195:Peroxidase / Q000378:metabolism; D011719:Pyrazines / Q000627:therapeutic use*; D011897:Random Allocation; D051381:Rats; D017208:Rats, Wistar; D012128:Respiratory Distress Syndrome / Q000097:blood / Q000188:drug therapy* / Q000209:etiology
D000894:Anti-Inflammatory Agents, Non-Steroidal; D016209:Interleukin-8; D011719:Pyrazines; D009195:Peroxidase; C017953:tetramethylpyrazine